Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: "Real World" Data From Germany

Krischan Braitsch; Laura K. Schmalbrock; Paul Jung; Irmgard Bumeder; Philipp Kiewe; Judith S. Hecker; Mareike Verbeek; Jörg Westermann; Lars Bullinger; Ulrich Keller; Florian Bassermann; Jan Krönke; Katharina S. Götze; Kathrin Rieger

doi:10.1097/HS9.0000000000000759

Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: "Real World" Data From Germany

Krischan Braitsch, Laura K. Schmalbrock, Paul Jung, Irmgard Bumeder, Philipp Kiewe, Judith S. Hecker, Mareike Verbeek, Jörg Westermann, Lars Bullinger, Ulrich Keller, Florian Bassermann, Jan Krönke, Katharina S. Götze, Kathrin Rieger

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	E759
Journal	HemaSphere
Volume	6
Issue number	9
DOIs	https://doi.org/10.1097/HS9.0000000000000759
State	Published - 9 Sep 2022
Externally published	Yes

Access to Document

10.1097/HS9.0000000000000759

Cite this

Braitsch, K., Schmalbrock, L. K., Jung, P., Bumeder, I., Kiewe, P., Hecker, J. S., Verbeek, M., Westermann, J., Bullinger, L., Keller, U., Bassermann, F., Krönke, J., Götze, K. S., & Rieger, K. (2022). Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: "Real World" Data From Germany. HemaSphere, 6(9), E759. https://doi.org/10.1097/HS9.0000000000000759

@article{e5f56bd3c3e54a8c9c20b7e195392348,

title = "Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: {"}Real World{"} Data From Germany",

author = "Krischan Braitsch and Schmalbrock, {Laura K.} and Paul Jung and Irmgard Bumeder and Philipp Kiewe and Hecker, {Judith S.} and Mareike Verbeek and J{\"o}rg Westermann and Lars Bullinger and Ulrich Keller and Florian Bassermann and Jan Kr{\"o}nke and G{\"o}tze, {Katharina S.} and Kathrin Rieger",

year = "2022",

month = sep,

day = "9",

doi = "10.1097/HS9.0000000000000759",

language = "English",

volume = "6",

pages = "E759",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "Wolters Kluwer Health",

number = "9",

}

Braitsch, K, Schmalbrock, LK, Jung, P, Bumeder, I, Kiewe, P, Hecker, JS, Verbeek, M, Westermann, J, Bullinger, L, Keller, U, Bassermann, F, Krönke, J, Götze, KS & Rieger, K 2022, 'Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: "Real World" Data From Germany', HemaSphere, vol. 6, no. 9, pp. E759. https://doi.org/10.1097/HS9.0000000000000759

Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: "Real World" Data From Germany. / Braitsch, Krischan; Schmalbrock, Laura K.; Jung, Paul et al.
In: HemaSphere, Vol. 6, No. 9, 09.09.2022, p. E759.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine

T2 - "Real World" Data From Germany

AU - Braitsch, Krischan

AU - Schmalbrock, Laura K.

AU - Jung, Paul

AU - Bumeder, Irmgard

AU - Kiewe, Philipp

AU - Hecker, Judith S.

AU - Verbeek, Mareike

AU - Westermann, Jörg

AU - Bullinger, Lars

AU - Keller, Ulrich

AU - Bassermann, Florian

AU - Krönke, Jan

AU - Götze, Katharina S.

AU - Rieger, Kathrin

PY - 2022/9/9

Y1 - 2022/9/9

UR - http://www.scopus.com/inward/record.url?scp=85179112321&partnerID=8YFLogxK

U2 - 10.1097/HS9.0000000000000759

DO - 10.1097/HS9.0000000000000759

M3 - Letter

AN - SCOPUS:85179112321

SN - 2572-9241

VL - 6

SP - E759

JO - HemaSphere

JF - HemaSphere

IS - 9

ER -

Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: "Real World" Data From Germany

Access to Document

Other files and links

Cite this